BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26067064)

  • 21. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells.
    McLaren JE; Zuo J; Grimstead J; Poghosyan Z; Bell AI; Rowe M; Brennan P
    J Gen Virol; 2009 Sep; 90(Pt 9):2239-50. PubMed ID: 19439556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells for the induction of EBV immunity.
    Subklewe M
    Recent Results Cancer Res; 2002; 159():38-43. PubMed ID: 11785842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL; Zuo J; Abbott RJ; Shannon-Lowe C; Tierney RJ; Hislop AD; Rowe M
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
    Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
    J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.
    Vogl BA; Fagin U; Nerbas L; Schlenke P; Lamprecht P; Jabs WJ
    J Med Virol; 2012 Jan; 84(1):119-31. PubMed ID: 22095540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
    Piriou ER; van Dort K; Nanlohy NM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2005 Mar; 35(3):796-805. PubMed ID: 15724243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent dendritic cell vaccine loaded with latent membrane protein 2A (LMP2A).
    Chen Y; Yao K; Wang B; Qing J; Liu G
    Cell Mol Immunol; 2008 Oct; 5(5):365-72. PubMed ID: 18954560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
    Chen A; Zhao B; Kieff E; Aster JC; Wang F
    J Virol; 2006 Oct; 80(20):10139-50. PubMed ID: 17005691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
    Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mouse model for acute Epstein-Barr virus infection.
    Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes.
    Wang B; Yao K; Liu G; Xie F; Zhou F; Chen Y
    Cell Mol Immunol; 2009 Apr; 6(2):97-103. PubMed ID: 19403058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
    Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
    Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.
    Zhang B; Zong Y; He J; Zhong B; Lin S
    Chin Med J (Engl); 2003 Jun; 116(6):913-7. PubMed ID: 12877806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH; Wolf H; Minarovits J
    Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.
    Smith C; Beagley L; Khanna R
    J Virol; 2009 Jun; 83(12):6192-8. PubMed ID: 19357166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.